Abstract. Osteosarcoma (OS) is one of the most common malignant bone tumors. Despite the advancement of diagnosis and treatment for OS, the prognosis remains poor. We investigated the proliferation inhibitory effect of all-trans retinoic acid (ATRA) for human OS and the possible mechanism underlying this effect. We examined the proliferation inhibition and apoptosis-inducing effects of ATRA in 143B OS cells. We validated this effect by exogenously expressing the retinoic acid receptor alpha (RARα) in 143B OS cells and injecting the cells into nude mice. We explored the possible mechanism for the proliferation inhibitory effect of ATRA on OS cells and multipotential progenitor cells by detecting osteogenic markers. We demonstrated that the endogenous retinoic acid receptor and retinoid X receptor are all detectable in the commercially available OS cell lines and in primary osteosarcoma cells. ATRA inhibits the proliferation of OS cells in a concentration-dependent manner, as well as induces apoptosis in 143B OS cells. The exogenous expression of RARα inhibits the tumor growth and cell proliferation in vivo. The alkaline phosphatase activity, protein levels of osteopontin (OPN) and osteocalcin (OCN) are all promoted by ATRA in OS cells and mouse embryonic fibroblasts (MEFs), at least by activating the Smad signaling pathway. Collectively, our results strongly indicate that ATRA can inhibit the tumor growth of OS by promoting osteogenic differentiation in OS cells, which is mediated in part by activating Smad signaling. Therefore, combination of ATRA with other current chemotherapy agents may be a promising therapy strategy for OS treatment.
Introduction
Osteosarcoma (OS) is one of the most common non-hematologic malignant bone cancers, mainly occurring in children and adolescents. Although chemotherapy and other regiments have been introduced for OS management, few patients with OS can achieve long-term disease-free status. This may be due to the high propensity for pulmonary metastasis and relapse of OS, as well as the serious adverse effects of current chemotherapy agents (1) . To date, the molecular pathogenesis of OS is not fully understood. Although some genetic or acquired conditions can increase the risk for OS incidence, such as patients with hereditary retinoblastoma have a high risk for OS (2, 3) , a variety of genetic alterations resulting in inactivating tumor suppressor genes and over-expression of oncogenes have been reported in OS (4) (5) (6) (7) , it is still unclear how much these contribute to the development of OS.
Increasing evidence suggests that defects in osteogenic differentiation may lead to OS development (7, 8) . Osteogenic differentiation is a multi-step process that needs to be well orchestrated in the progenitor cells (9) (10) (11) . If the progenitor cell deposits defects at the early stage of osteogenic differentiation, it may lead to the development of less differentiated and more malignant OS tumors. On the contrary, OS tumors may be lower grade if they are caused by defects at the later stage in osteogenic differentiation.
In order to improve the prognosis of OS, it is necessary to explore some new treatment strategies, in which differentiation therapy is one of the promising choices (12) (13) (14) . A few agents have been used as differentiation promoter to treat certain cancers (15) (16) (17) (18) . ATRA is one of them and has been used to treat acute promyelocytic leukemia (APL) successfully (19) .
Retinoic acids (RAs) are derivates of vitamin A and play an important role in embryonic development and function maintenance of vital organs in adult. RAs regulate differentiation and metabolism by activating the RA receptor (RAR) that bind to the retinoid X receptor (RXR) as a heterodimer. The dimer binds to a regulatory DNA element (retinoic acid response elements, RAREs) and regulates the transcription level of downstream target genes. RAR agonists, such as ATRA, have been shown to promote the terminal differentiation of progenitor cells and cancer cells (15, 20) . ATRA can activate the retinoic acid signaling pathway and cross-talk with other pathways, such as mitogen activated protein kinase (MAPKs) (21), NF-κB (22) TGF-β (23, 24) and Notch (25) . Thus, we investigated the anti-proliferation effect of ATRA in human OS cells. We found that the endogenous RAR and RXR present in the commercial available OS cell lines and the primary OS cells as previously described (26) . ATRA can inhibit proliferation and induce apoptosis in OS cells. In the in vivo study, we found that exogenous expression of RARα inhibits OS tumor growth. Further analysis indicates that ATRA can promote osteogenic differentiation in OS cells and MEFs, as well as increase the phosphorylation of Smad1/5/8. Taken together, our data suggest that ATRA can inhibit the OS cell proliferation, this function may be mediated at least by promoting OS cells to undergo osteogenic differentiation through activating Smad signaling.
Materials and methods
Cell culture and reagents. OS cell line 143B was purchased from American Type Culture Collection, and ATRA from Bimol. Antibodies were from Santa Cruz Biotechnology. All other reagents were purchased form Sigma-Aldrich or Fisher Scientific, unless otherwise indicated. Cells were maintained in the Dulbecco's modified Eagle's medium (DMEM) with 10% fetal bovine serum (FBS), 100 U/ml of penicillin and 100 µg/ml of streptomycin at 37˚C in 5% CO 2 .
Recombinant adenovirus expressing red fluorescent protein and RARα. Recombinant adenoviruses expressing red fluorescent protein (RFP, Ad-RFP) and RARα, (Ad-RARα) were constructed with AdEasy system as reported (27) . Ad-RFP was used as a mock control.
Isolation of MEFs.
MEFs were isolated from post coitus day 12.5 mice, as previously described (28) . Each embryo was dissected into 10 ml sterile PBS, voided of its internal organs, and sheared through an 18-gauge syringe in the presence of 1 ml 0.25% trypsin and 1 mM EDTA. After 15-min incubation with gentle shaking at 37˚C, DMEM with 10% FBS was added to inactivate trypsin. The cells were plated on 100-mm dishes and incubated for 24 h at 37˚C. Adherent cells were used as MEFs. Aliquots were kept in a liquid nitrogen tank. All MEFs used in this study were less than five passages.
Protein harvest and Western blot assay. Cell lysates were denatured and loaded on to SDS-PAGE gel. After electrophoresis, proteins were transferred to polyvinylidene fluoride (PVDF) membrane, and then was blocked with 5% non-fat milk at room temperature for 1 h and probed with first antibody for 2 h, followed by 25-min incubation with second antibody conjugated with horseradish peroxidase, then developed with SuperSignal West Pico Chemiluminescent Substrate kit. Images were taken with Bio-Rad imaging system.
Cell proliferation assay. Sub-confluent cells were seeded in 24-well plates and treated with different concentrations of ATRA or dimethyl sulfoxide (DMSO) as control. At the scheduled timepoints, cells were stained with crystal violet to visualize the cell viability, followed by quantitative analysis with ImageJ (1.42q).
Apoptosis staining. Sub-confluent cells were seeded in 6-well plates and treated with 80 µM ATRA or DMSO. Cells were collected 48 h later, followed by staining for apoptosis detection with Vybrant Apoptosis Assay Kit (V-23201, Invitrogen, USA). For fluorescence activated cell sorting (FACS) assay, cells were collected and subjected to staining with propidium iodide (PI) and Annex-V FITC (no. KGA104, KeyGen Biotech, China) for apoptosis.
Establishment of the stable OS cell line expressing firefly luciferase.
Stably expressing firefly luciferase 143B cell line (143B-Luc) was generated by using a retroviral vector and 143B cells as described (29) .
Orthotopic OS tumor animal model establishment. All animal experiments follow the guideline of Institutional Animal Care and Use Committee of The University of Chicago (IACUC). Athymic mice (female, 4-6-week old, 5/group) were obtained from Harlan Sprague Dawley (USA).
143B-luc cells were infected with Ad-RARα or Ad-RFP adeno virus. Cells were collected and resuspended in cold (4˚C) phosphate buffer solution (PBS) to a final density of 2x10 7 cell/ ml. Cells in 50 µl of cold PBS were injected into the proximal tibia of athymic mice (female, 4-6-week old). Animals were sacrificed 5 weeks after injection. The tumor samples were retrieved for histochemical assay.
In vivo bioluminescence imaging. Animals were anesthetized with isoflurane attached to a nose-cone mask within Xenogen IVIS200 imaging system. Animals were injected with D-Luciferin sodium salt (Gold Biotechnology) at 100 mg/kg in 0.1 ml sterile PBS. The pseudoimage were obtained by superimposing the emitted light over the gray scale photographs of the animals. Quantitative analysis was done with the Xenogen Living Image Software (250.1).
Histologic and immunohistochemical staining. Animals were sacrificed at the end of test, the retrieved tumor samples were fixed in 10% formalin (decalcified if necessary) and embedded in paraffin. Sections of the embedded specimens were stained with hematoxylin and eosin (H&E). For proliferating cell nuclear antigen (PCNA) immunohistochemical staining, sections were deparaffinized and then rehydrated in graduated fashion. The deparaffinized samples were subjected to antigen retrieval and fixation. Slides were blocked and probed with PCNA antibody. PCNA was visualized by 3,3'-diaminobenzidine (DAB) staining, mouse IgG was run as a negative control.
Alkaline phosphatase activity assay. Alkaline phosphatase (ALP) activities were detected by a modified protocol, using p-nitrophenyl phosphate as a substrate, as described (30, 31) . Briefly, sub-confluent OS cells were seeded in 24-well plates and treated with different concentrations of ATRA. On day 5 and 7, the cells were lysed and the lysates were centrifuged to discard the precipitation. The supernatant was used for ALP activity test by colorimetric assay. The total protein level was assessed by BCA for normalizing the ALP activity. Each assay was performed in triplicate.
Luciferase reporter assay. Cells were seeded in T25 flask and transfected with 3 µg of firefly luciferase reporter plasmids. Twelve hours later, trypsinized cells were seeded to 24-well plates, then treated with ATRA or DMSO. Lysed cells, and the lysates were subjected to luciferase assays using luciferase assay kit (no. TM040, Promega, USA) at 24 h, total protein level was assessed by BCA for normalizing the firefly luciferase activity. Each assay was done in triplicate.
Statistical analysis. Data presented are the results of at least two independent experiments performed in triplicate. Microsoft Excel was employed to calculate the standard deviations. The differences were analyzed using the Student's t-test. A p<0.05 was defined as statistically significant.
Results

Endogenous expression of RAR and RXR in human OS cell lines and primary OS cells.
We first detected the endogenous expression level of RAR and RXR in the three commercially available OS cell lines and seven primary human OS cells as previously described (26) . The Western blotting results show that RARα and RXRα were expressed in all of the cells (Fig. 1) . We also tested the subtype receptors of RAR and RXR with real-time PCR, each subtype receptor can be detected in the OS cells (data are not shown). Our results suggest that the retinoic acid signaling is available in OS cells.
ATRA inhibits the proliferation of OS cells.
To test the proliferation inhibitory effect of ATRA on OS cells, we employed the crystal violet staining. The result shows that the proliferation of 143B cells was inhibited by ATRA with a concentration and time-dependent fashion ( Fig. 2A) . The staining result was quantified with ImageJ (1.42q) (Fig. 2B) . The assay was done in triplicate and the representative result is shown.
ATRA induces apoptosis in OS cells. Next, we tested whether ATRA could induce apoptosis in OS cells. The 143B OS cells were treated with indicated concentrations of ATRA or DMSO for 12 and 24 h. Then, cells were subjected with FACS analysis (Fig. 3A) , or were lysed and subjected to Western blot test for detecting caspase-3 protein level (Fig. 3B) . The results show that ATRA can induce apoptosis in 143B cells, and the caspase-3 protein increased at 12 and 24 h with a concentration-dependent fashion. Cells were also subjected to apoptosis staining after being treated with ATRA for 48 h, the result shows that the apoptosis apparently occurred when treated with 80 µM ATRA (Fig. 3C ). These data indicate that ATRA can induce apoptosis in OS cells.
Exogenous expression of RARα inhibits OS tumor growth in vivo.
To elucidate whether ARTA can inhibit the proliferation of OS cells in vivo, we tested tumor growth inhibitory effect of ATRA by exogenous expressing RARα receptor in OS cells. We took advantage of the reported orthotopic xenograft model of OS tumor for this test (32) . The luciferase tagged 143B OS cells were infected with Ad-RARα or Ad-RFP (as mock control), then were injected into athymic nude mice intratibially and Xenogen images were taken weekly (Fig. 4A) . The quantitative results indicate that the exogenous expression of RARα can inhibit the OS tumor growth (Fig. 4B) . Retrieved samples from the OS tumors were fixed and paraffin-embedded. The sections were subjected to H&E staining and PCNA immunohistochemical staining ( Fig. 4C and D) . The result validates that ATRA can inhibit the proliferation of OS cells in vivo.
ATRA promotes OS cells to undergo osteogenic differentiation by activating Smad signaling in OS cells.
Osteogenic differentiation from osteoprogenitor cells to osteocyte is a well orchestrated process. Related research has shown that OS deposits osteogenic differentiation defects. We tested the possibility of ATRA to promote OS cells to undergo osteogenic differentiation. Our results show that ATRA can increase the ALP activity in 143B OS cells on day 5 and 7 ( Fig. 5A) , the protein level of OPN and OCN are all increased on day 9 and 11 ( Fig. 5B) . To further understand the mechanism underlying the osteogenic differentiation induced by ATRA in OS cells, we used bone morphogenic protein (BMP) receptorspecific Smad binding site luciferase reporter (BMPR-Smad, p12XSBE-Luc) (33) and Western blotting to test the activation of Smad signaling. The results show that ATRA can promote the reporter luciferase activity in a concentration-dependent fashion (Fig. 5C ), and increase the phosphorylation level of Smad-1/5/8 (Fig. 5D) , which is critical for transducing osteogenic signals. In MEFs cells, we obtained similar results. ATRA increased the ALP activities (Fig. 5E ), protein expression level of OPN and OCN (Fig. 5F ), luciferase activity of p12XSBE-Luc luciferase reporter (Fig. 5G) , and the phosphorylation level of Smad-1/5/8 compared to that of the control group (Fig. 5H) . These results suggest that the proliferation inhibitory effect of ATRA on 143B OS cells may result from the promoted osteogenic differentiation, which was at least partly mediated by activating Smad signaling.
Discussion
OS is a common bone cancer. The current management include chemotherapy, radiotherapy and surgical excise, with marginal improvement of the poor prognosis. It is necessary to find less toxic and more efficacious therapy strategies for OS treatment.
Herein, we present a new management strategy for OS with ATRA.
In this study, we demonstrated that the endogenous retinoic acid signaling is available in all tested OS cell lines or OS cells retrieved from primary OS tumors. This evidence suggests that retinoic acid signaling may execute unknown committed functions when activated by their endogenous or exogenous agonists in OS cells. Our results indicate that ATRA can inhibit proliferation and induce apoptosis in OS cells. Exogenous RARα can inhibit OS tumor growth in an orthotopic animal model in nude mice (32) . Further analysis shows that ATRA can promote the osteogenic differentiation in OS cells and MEFs, which may be mediated by activating Smad signaling pathway.
OS is characterized by a bimodal distribution, with the first peak in children and adolescents, the second smaller peak in elderly adults, high incidence of pulmonary metastasis and varying degree of osteoblastic differentiation (4, 5, 7, 34) . To date, our knowledge of OS molecular pathogenesis remains rather limited, so it is hard to find specific targets or efficacious treatment to eliminate OS or improve the prognosis of OS. The successful clinical treatment for OS also faces various challenges. 1) The serious adverse effect of the chemotherapy drugs, because most of them are non-specific cytotoxic agents and mostly target the rapid proliferation tumor cells (10, 16, 35) , and 2) the OS harbors propensity to lung metastasis and high recurrence, which produce the majority of OS related mortality (34) .
Differentiation therapy may be another promising alternative for certain malignancies. Nuclear receptors, such as RAR and RXR, have been documented as potential targets for cancer treatment (35) (36) (37) . ATRA, the agonist of RAR, has been used for the management of acute promyelocytic leukemia (APL), one of the most promising mechanisms of ATRA on APL is to promote the immature cells undergo terminal differentiation (19, 38) . ATRA has also been documented as differentiation and/or apoptosis inducer for the management of certain other cancers, including breast cancer, bladder cancer, Kaposi's sarcoma and neuroblastoma (19, 39) .
Although the molecular mechanism of OS remains unclear, with the expansion of our knowledge on stem cells and cancer, more and more evidence suggests that OS may be a kind of differentiation disease (5, 8, 40) . Our results show a broad range of ALP activity in OS cell lines or OS cells derivated from the primary OS tumors (data are not shown). Osteoprogenitors differentiate to osteocytes controlled by a variety of signalings (11, 30, (41) (42) (43) (44) (45) (46) . Some genetic or epigenetic changes can disturb the osteogenic differentiation process and finally cause the development of OS. This opinion is supported by the following evidence: first, most of OS have the features of undifferentiated osteoblasts (4, 5, 7, 34) . Second, some agents can drive OS cells to undergo osteogenic differentiation (5, 35) . Third, the disturbance of function of RB can attenuate the osteogenic differentiation, because RB is one of the important regulators of Runx-2, a pivotal transcription regulator for osteogenic differentiation (47, 48) . Fourth, some osteogenic agents fail to drive osteogenic differentiation in most OS cells and promote OS tumor cell growth, such as osteogenic BMPs (5). Finally, in Ewing's sarcoma (EWS), EWS/ETS fusion protein can block the osteogenic and adipogenic differentiation in marrow stromal stem cells (49) . The expression of EWS/FLI-1 oncogene can lead to EWS like tumors and EWS/FLI-1 knockdown can drive some ESW cells to differentiate along adipogenic or osteogenic lineages when some appropriate cocktails were used (50, 51) . Taken together, differentiation therapy, by driving terminal osteogenic differentiation or bypassing the differentiate defects, may be an efficacious regimen or adjuvant combined with the conventional therapy for OS treatment.
Our results indicate that ATRA can inhibit the proliferation of OS. This effect was recapitulated in a well established orthotropic animal model through exogenous expressing RARα. Further analysis suggested that the proliferation inhibitory effect of ATRA on OS cells may be result from promoting the OS cells to undergo osteogenic differentiation. It is possible to establish a novel therapy strategy by combining ATRA with traditional chemotherapy agents for the treatment of OS, which may increase the anti-tumor effects and attenuate the adverse effect of the traditional agents. Future experiments will focus on the possible mechanism underlying the effect of ATRA on OS cells and the possibility of ATRA combine with some traditional agents as a new treatment for OS cells.
The role of ATRA in osteogenic differentiation is controversial, some reports indicate that ATRA can inhibit osteogenesis and promote adipogenesis (46, 52, 53) . However, our results in this study and some other results before indicate that ATRA can promote osteogenic differentiation (20) . In our opinion ATRA and its analogs are non-specific differentiation promoting agents. It is possible that the outcomes of ATRA treatment may largely depend on the cell types/stages of progenitors used.
Taken together, our study demonstrated that ATRA can inhibit the proliferation of OS cells in vivo and in vitro by promoting OS cells to undergo osteogenic differentiation, which may be mediated by activating Smad signaling.
